Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Phase 3 Completed 89 enrolled Novartis

RandomizedCrossoverTriple-blindTreatment

Summary

This study will evaluate the onset of action of indacaterol (150 and 300 µg) as compared to placebo, salbutamol 200 µg and salmeterol/fluticasone 50/500 µg

Timeline

Start: 2008-04
Primary completion: 2008-08
Completion: 2008-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Indacaterol	Other / unclassified	150 ug	Inhaled
Subject	Indacaterol	Other / unclassified	300 ug	Inhaled
Subject	Salbutamol	Unknown	200 ug	Inhaled
Subject	Salmeterol/fluticasone	Unknown	50 ug	Inhaled
Subject	Salmeterol/fluticasone	Unknown	500 ug	Inhaled

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Summary

Timeline

Drugs

Indications